Editorial team of Nature Reviews Drug Discovery www.nature.com/nrd https://bsky.app/profile/natrevdrugdiscov.nature.comhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mvksklexq22lThis Review in the September issue covers the clinical landscape for agonistic antibody-based immunotherapy for cancer and immune disorders, and mechanistic insights that could broaden its scope https://www.nature.com/articles/s41573-026-01442-2 rdcu.be/9y7jJZbHxe8a15 Sep 2026 14:11 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mvksklexq22lhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mviazzkv7c2hThis Review in the September issue discusses targeting autophagy to limit malignant transformation, potentiate cancer cell death driven by existing drugs and restore immunosurveillance in support of immunotherapies https://www.nature.com/articles/s41573-026-01449-9 rdcu.be/MMNGMaj8ifwa14 Sep 2026 13:52 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mviazzkv7c2hhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mvai6rl4nk2mNewest glue degrader nabs multiple myeloma approval https://www.nature.com/articles/d41573-026-00147-w Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors11 Sep 2026 11:39 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mvai6rl4nk2mhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mv6as5jzp22mFor readers interested in the potential of in vivo CAR-T cell therapies for cancer and autoimmune diseases, here's a comprehensive review by pioneers in the field rdcu.be/koc33UDidsza https://nature.com/articles/s41573-025-01291-510 Sep 2026 14:21 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mv6as5jzp22mhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mv6an2f2fs2qThe landscape for in vivo CAR T cell therapies https://www.nature.com/articles/d41573-026-00140-3 This article analyses the pipeline of in vivo CAR-T therapies for cancer and autoimmune disorders, highlighting trends in delivery technologies, targets and indications.10 Sep 2026 14:18 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mv6an2f2fs2qhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mv3qqfqqpk27This Review in the September issue discusses the evolving landscape of drugs targeting claudins in cancer, including monoclonal antibodies, CAR-T cell therapies, antibody-drug conjugates and bispecific antibodies https://www.nature.com/articles/s41573-026-01450-2 rdcu.be/vcwJ2mgqPs3a09 Sep 2026 14:29 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mv3qqfqqpk27https://bsky.app/profile/natrevdrugdiscov.nature.com/post/3muz62obu222gStrengthening muscle for healthy ageing: innovative treatments for sarcopenia https://www.nature.com/articles/s41573-026-01514-3 rdcu.be/NVL9v7ueUwAa This new Review discusses strategies targeting mitochondrial function, autophagy, anabolic signalling, vascularization, inflammageing and regeneration08 Sep 2026 13:49 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3muz62obu222ghttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3muwo6uhs7k2iUn-siloed biomedical opportunities https://www.nature.com/articles/d41573-026-00148-9 Edith Heard, CEO of the Francis Crick Institute in London @crick.ac.uk, discusses the need to break down biomedical boundaries07 Sep 2026 14:00 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3muwo6uhs7k2ihttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mup6taewmk2zThe FDA recently approved the first orexin receptor agonist for narcolepsy https://nature.com/articles/d41573-026-00135-0 Oveporexton is anticipated to transform the treatment of this sleep disorder, and potential additional applications have led to the class being dubbed the GLP-1s of neuroscience04 Sep 2026 14:36 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mup6taewmk2zhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mumlycwzsc2pFor readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive Review https://www.nature.com/articles/s41573-025-01349-4 rdcu.be/97VgTv2SaRTa03 Sep 2026 13:54 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mumlycwzsc2phttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3muk5wprxds2lSolute carrier membrane transporters: emerging targets in CNS disorders https://www.nature.com/articles/s41573-026-01513-4 rdcu.be/uQeAYKzFg8Ua This new Review discusses targeting SLC transporters in neurodegenerative diseases, autism spectrum disorders and epilepsy02 Sep 2026 14:37 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3muk5wprxds2lhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3muhmgwkjoc25For readers interested in JAK inhibitors for autoimmmune diseases, such as Roivant's brepocitinib that has just been approved by the FDA for dermatomyositis, here's a review on pharmacological targeting of the JAK-STAT pathway https://nature.com/articles/s41573-025-01336-9 rdcu.be/rpNrcuDMf4ha01 Sep 2026 14:19 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3muhmgwkjoc25https://bsky.app/profile/natrevdrugdiscov.nature.com/post/3muhma4wznc2hOur September issue is live! Read about brain-shuttle biologics, targeting claudins in cancer, agonist antibody-based immunotherapies, autophagy modulation in cancer and more here https://nature.com/nrd/volumes/25/issues/901 Sep 2026 14:15 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3muhma4wznc2hhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mtyinkpre22nTowards precision psychiatry: initial foundations and future directions https://www.nature.com/articles/s41573-026-01509-0 rdcu.be/fCeOU This new Perspective discusses how to align drug development with underlying neural dysfunctions using patient-specific measures of brain function such as EEG26 Aug 2026 14:01 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mtyinkpre22nhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mtyaaxrawk2iFor neurologists who want to stay current, Springer Nature has a new resource made for you. Nature Briefing: Clinical Neurology brings together key clinical developments and research from leading journals in the field in a weekly newsletter. Sign up is free https://go.springernature.com/int1/briefing/neurology26 Aug 2026 11:31 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mtyaaxrawk2ihttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mtlzanbe3k2wFor readers interested in mRNA therapeutics, including neoantigen-based therapeutic cancer vaccines such as Moderna and Merck's intismeran autogene, here's a recent Review https://www.nature.com/articles/s41573-026-01459-7 rdcu.be/fBiGZ21 Aug 2026 14:53 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mtlzanbe3k2whttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mt2dc4w3i22mIn the wake of the FDA approval of Takeda's first-in-class orexin 2 receptor agonist oveporexton for narcolepsy last week, there is a burgeoning pipeline of orexin modulators for a range of central nervous system disorders https://nature.com/articles/d41573-026-00135-014 Aug 2026 14:05 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mt2dc4w3i22mhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3msv7hwemv22aOncolytic virus nabs FDA approval https://nature.com/articles/d41573-026-00136-z Replimune’s vusolimogene oderparepvec (Tudriqev, also known as RP1) has received accelerated approval for use in combination with the PD-1 blocker nivolumab for advanced melanoma. It is the second oncolytic virus to reach the US market12 Aug 2026 13:13 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3msv7hwemv22ahttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3mssso62vm22hFor readers interested in targeted protein degradation, this Perspective in the August issue discusses safety considerations in the development of PROTAC and molecule glue drug candidates that recruit the E3 ligase cereblon https://www.nature.com/articles/s41573-026-01426-2 rdcu.be/fzgJJ11 Aug 2026 14:19 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3mssso62vm22hhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3msqbv6hvds2kOrexin receptor agonist secures landmark narcolepsy approval https://nature.com/articles/d41573-026-00135-0 As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists10 Aug 2026 14:13 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3msqbv6hvds2khttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3msq7xtways2bArtificial intelligence in drug discovery — what it is, where we stand and the path forward https://nature.com/articles/s41573-026-01496-2 rdcu.be/fyUFz10 Aug 2026 13:39 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3msq7xtways2bhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3msdr5jtmxk2fFor readers interested in 'in vivo' CAR-T therapies for cancer and autoimmune diseases, here's a comprehensive review from pioneers in the field https://nature.com/articles/s41573-025-01291-5 rdcu.be/fx2H305 Aug 2026 14:42 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3msdr5jtmxk2fhttps://bsky.app/profile/natrevdrugdiscov.nature.com/post/3msbaf2dkak2uFor readers interested in mRNA therapeutics, this Review discusses progress and lessons learned from candidates in clinical trials for applications including cancer immunotherapy, genome editing and in vivo CAR-T cell therapy https://www.nature.com/articles/s41573-026-01459-7 rdcu.be/fxNFo04 Aug 2026 14:36 +0000at://did:plc:3botkcmtgio7ah7eg4ogb7te/app.bsky.feed.post/3msbaf2dkak2u